PD-L1 expression and TMB are not related, but increased and higher PD-L1 levels predicts better clinical benefits, according to a study of 240 advanced NSCLC patients treated with PD-1 blockades 45. This evidence concerns the gene CD274 and non-small cell lung carcinoma.